How the world learns to live with covid-19

From pandemic to epidemic

10/17/2021 2:50:00 AM

The harm from endemic covid may eventually fall somewhere between that of influenza and the other common coronaviruses

From pandemic to epidemic

V-2 will end up more like the other endemic coronaviruses than flu. Jabs may still be needed periodically for the most vulnerable but Dr Heymann thinks that even in bad covid seasons deaths may not get anywhere as high as those from influenza (using current flu vaccines).

Regardless of where endemic covid ends up, the world is not yet there. Hospitalisations and deaths are soaring in eastern Europe where vaccination campaigns have been poor. Large swathes of the populations of New Zealand and Australia, which have had low infection rates as a result of stringent lockdowns and slow vaccination roll-outs, are still immunologically naive. Countless people have yet to be reached by either virus or vaccine. When the virus arrives in parts of the world without immunity, the result will be spikes in disease and death.

Not yet out of the woodsIn the medium term even highly vaccinated places will see flare ups. Britain, which ditched its precautions earlier than most other European countries, shows that covid can bear down on hospitals even in places with the benefit of high levels of vaccination (see chart 2). In September covid patients occupied 25-35% of its intensive-care beds. They tend to stay there for two to three weeks, leaving less room for post-operative care patients, who need a bed for only a couple of days. But in Britain, as in the rest of Europe, 80-90% of those hospitalised with covid are unvaccinated. The divide between vaccinated and unvaccinated is even starker when it comes to death. Covid is now a leading cause of death among unvaccinated Britons. In the first half of 2021 just 1% of all deaths in fully vaccinated people in Britain were because of covid. Among the unvaccinated, the disease caused 37% of deaths. headtopics.com

Globally, these waves of infection will be dampened by the collective immunity that runs through and around the remaining pockets of the immunologically naive. Over time, these spikes will become ever rarer. And the world will stumble towards endemicity. What endemicity looks like and the speed with which countries get there will depend on three things: what proportion of a given population are immune to the virus and the quality and durability of that immunity; how the disease can be treated; and how the virus evolves.

Immunity is hard to measure. The immune system is complex and poorly understood. Both the quantity and quality of the antibodies it produces matter. “Up to six months after vaccination, the immune system is still in the process of optimising and perfecting its response,” says Ali Ellebedy, an immunologist at the Washington University School of Medicine in Missouri. “Antibodies induced in the first two or three months are being slowly replaced by much better antibodies in terms of binding affinity to the spike. That’s hard to see. Quantitatively there are fewer antibodies but qualitatively things are improving.”

Nor are antibody levels a definitive marker of protection. “People get covid with very high antibody levels. It’s not that there is an obvious cut-off where you can say ‘This high, you are protected’,” says Sarah Walker, an epidemiologist at Oxford University. But at a population level, a high prevalence of neutralising antibodies—which prevent a pathogen from infecting the body—means fewer infections.

Even without great insight into people’s individual or collective immunological state, the broader picture is clear. As the virus has spread through populations, the immune systems of those who survive have been training themselves on its shape, preparing antibodies to fight off future infection. The protection vaccines afford against infection wanes in the months after people receive them, but the training they give the immune system to prevent serious disease and death stays strong. headtopics.com

Vaccines have offered about a third of humanity a shortcut to endemicity, bypassing sections of the path that would otherwise have been far more deadly. Some 3.8bn people have had at least one shot, and 2.8bn are fully vaccinated. Add them to those who have survived infection and it looks as if over half the world’s population boasts some degree of immunity to covid.

Vaccines greatly reduce the risk of severe illness and death. They have saved hundreds of thousands of lives and let many health-care systems keep operating. Covid is the first pandemic for which the cyclical tussle between viral spread and evolution and developing immunity has been short-circuited so fast and on such a scale.

But the overwhelming majority of those who have acquired immunity in this less risky manner reside in wealthier countries. In poor places the majority have and will continue to do so via infection. The rate of vaccination, which surged through the first half of the year to reach some 43m doses administered per day in late June, had dropped to 30m doses per day by the end of September, although much of this decline is because of slowing vaccination in China. It is remarkable that humans have been able to administer vaccines faster than the virus is able to spread between people, but this now looks as though it is a phenomenon confined only to rich places.

At present, the world’s collective level of immunity to covid is nowhere near that for other endemic respiratory diseases. That is because all humans are exposed to older endemic diseases repeatedly through their lives, particularly as children. Every exposure offers a new chance to train the immune system. Dr Ellebedy says it will take decades for humanity to reach a comparable level of immunity to covid. The coming years, then, will be characterised by a slow process of cyclical decline that runs in tandem with a broadening and deepening of immunity through infection. headtopics.com

To everything there is a seasonEventually, once immunity is widespread enough, cases of covid will fall into a seasonal pattern similar to other endemic respiratory diseases that have been circulating for a much longer time. Rachel Baker of Princeton University, who studies how viruses respond to environmental conditions, says that she expects within five or six years the patterns of covid infections will become seasonal, like those of other endemic coronaviruses, rather than being driven by immunological naivety.

The fact that covid will almost certainly become a disease that humanity can live with is thanks not only to vaccines but also to the rapidly advancing treatments. Remdesivir, an antiviral, can reduce hospital admissions by 87% in high-risk patients if it is given in the first stage of covid. But it needs to be administered intravenously in a hospital setting. Antibody therapies, another kind of drug, are highly effective but are usually given in the same way.

AstraZeneca’s antibody drug,AZD7442, which is under regulatory review in America, solves some of these problems because it can be in injected in places like doctors’ surgeries. It will probably be expensive so will not be used widely. But it offers a quick shot of covid-fighting antibodies so will provide extra protection to those at risk even after vaccination such as the immunocompromised. A hit of antibodies will also be useful as prophylaxis both for those at high risk of catching the virus (such as health workers) and those likely to become very ill (those with underlying conditions such as cancer or diabetes or the elderly residents of care homes).

Cheaper oral antiviral drugs which will further reduce the burden that covid places on humans, and on the hospitals that treat them, are also on the way. Most promising is molnupiravir, made by Merck and Ridgeback, both drugmakers. Taken within five days of symptoms’ onset it reduced the risk of hospitalisation or death by about 50% in patients with mild or moderate covid.

Merck expects to supply 10m courses of the drug by the end of 2021. Pricing will be tiered, and so it will be affordable across the planet. Results from trials of similar drugs from Pfizer, Roche and Atea Pharmaceuticals could add to the antiviral arsenal.

Antivirals such as molnupiravir do not cure covid-19. But they make it much less dangerous. One worry, however, is that the virus will evolve to resist a single line of antiviral therapy. Peter Horby, a professor of emerging infectious diseases at Oxford University, warns of the need to consider using combinations of antivirals from the outset.

HIVantiviral drugs showed that resistance to single therapies arises quickly.These drugs will make covid easier to live with but governments and public-health authorities will still need to ensure that any outbreaks do not overwhelm health-care systems. Each winter the circulation of influenza will add to the challenge. It may make sense to once again take steps to reduce the transmission of the disease. In the rich world very few occasions should require going into the office with a respiratory complaint, especially in winter. Annual boosters and flu shots will help keep vulnerable people out of hospital.

Over all this hangs the inevitability of the coronavirus’s continued evolution, and the question of its impact. Any new variant that emerges is overwhelmingly likely to do so based on Delta, which has displaced virtually all the rest. If a new variant emerges which outcompetes Delta, it will eventually spread everywhere. The Beta variant, which is now being driven towards extinction, was better at defeating immunity than Delta is, but less good at spreading, and so receded.

A new variant that combined their traits would be a disaster. “Delta Plus”, a subvariant that has so far not taken off, has picked up mutations of the sort which characterised Beta, but no evidence suggests yet that this is leading to its wider spread or vaccine evasion. But the possibility of a Delta variant with Beta characteristics, as well as the need to keep people out of hospital, will always be a reason for limiting the spread of the disease. “We’re ill-equipped to predict the timeline,” says Daniel Altmann, an immunologist at Imperial College London, since coronavirus evolution is by its nature unpredictable.

Read more: The Economist »

American Music Awards 2021: The Full Winners List

The American Music Awards aired live from the Microsoft Theater in Los Angeles tonight at 8 p.m. ET/PT on ABC. Hosted by Cardi B, the star-studded awards show featured performances from BTS with Co…

Mevlid Kandili, which is the day of the last prophet Prophet Muhammad (SAV), will be realized on this day. Have a blessed mawlid. Sounds good for someone end of life yeah. Can't understand where here is something new.... Or here last year print We demand safety of Bangladeshi Hindus. ✊God gives us strength to protect our community.. savebangladeshhindus savebangladeshhindu Stopcommunalattack SaveBangladeshiHindus BangladeshiHinduWantSafety WeDemandSafety WeDemandJustice SaveHinduTemples SaveHumanity

thanks horrible

19 People Who Got Scammed By Life In The Worst Way PossibleBe careful who you trust. These pictures belong on /r/CrappyDesign.

US to donate more than 17 million Johnson & Johnson Covid-19 vaccines to African UnionThe US will donate more than 17 million doses of the Johnson & Johnson Covid-19 vaccine to the African Union, President Joe Biden announced on Thursday. LOL Insert Chappelle joke For all those who are new to this working from home Bitcoin trading options Here's a little tip: Get a trusted Bitcoin expert and stick to her earn_with_jenss Invest and play at similar times each day. Because : In times of chaos, your investment is your anchor to success Every illegal should be vaccinated as they come across the border! Oh then they may not be able to infect citizen’s. HouseGOP FAIRImmigration JudicialWatch HouseGOP

19 Wild Stories Of Bouncers Kicking People Out Of A Bar“The time I had to break up two cocktail waitresses fighting over a table that ended with one of them biting the other in the face.”

COVID-19 Live Updates: FDA to vote on Johnson & Johnson vaccine booster shot after Moderna approvedAn FDA expert panel will vote on whether to support or oppose a booster shot for the Johnson & Johnson COVID-19 vaccine. Follow Newsweek's liveblog for all the latest.

Australia's biggest city to end Covid-19 quarantine for international travelersSydney will end its Covid-19 quarantine for fully vaccinated international travelers from November 1, New South Wales Premier Dominic Perrottet said on Friday, October 15 foreshadowing the full return of overseas travel after more than 19 months. But coward scomo didn't allow it... We students are waiting from last 18 months... But doesn't care about us

Covid-19: Nisra records drop in virus-related deathsNisra says in the week up to 8 October, the virus was mentioned on the death certificates of 28 people.